Solid Biosciences Inc. (SLDB) Dividend History

Solid Biosciences Inc. is a biotechnology company focused on developing gene therapy and other innovative treatments for Duchenne muscular dystrophy (DMD), a rare genetic neuromuscular disorder. The company's pipeline aims to address the underlying genetic causes of DMD and improve quality of life for patients through advanced therapeutic approaches.

500 Rutherford Avenue, Charlestown, MA, 02129
Phone: 617-337-4680
Website: https://www.solidbio.com

Dividend History

Solid Biosciences Inc. currently does not pay dividends

Company News

Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight

The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options.

GlobeNewswire Inc.

Featured Companies: AMGN BMY CPIX RCKT
Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences, a life sciences company developing precision genetic medicines, announced its participation in two upcoming investor conferences, where the company's leadership will discuss its pipeline of gene therapy candidates for neuromuscular and cardiac diseases.

GlobeNewswire Inc.
Rocket Lab stock downgraded by Morgan Stanley due to revised growth outlook By Investing.com - Investing.com

JPMorgan has upgraded Solid Biosciences' stock from Neutral to Overweight, citing the company's promising gene therapy pipeline and the favorable regulatory environment for its products.

Investing.com
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee.

GlobeNewswire Inc.
This Planet Fitness Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Max Rakhlenko upgraded the rating for Planet Fitness, Inc. (NYSE:PLNT) from Hold to Buy, while raising the price target from $66 to $92. Planet Fitness shares fell 0.4% to close at $72.73 on Friday. See how other analysts view this stock. Roth MKM analyst Eric Handler upgraded Cinemark Holdings, Inc. (NYSE:CNK) from Neutral to Buy and boosted the price target from $19 to $26. Cinemark shares ...Full story available on Benzinga.com

Benzinga

Featured Companies: CNK DMRC PLNT SIRI

Dividend data last updated 06/07/2025 04:37:53 UTC